" class="no-js "lang="en-US"> Philippe Villain-Guillot - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Philippe Villain-Guillot

Philippe Villain-Guillot

About Philippe Villain-Guillot

Philippe Villain-Guillot has been Nosopharm’s chief executive officer since co-founding the company in 2009. In this first entrepreneurial venture, he grew the company to include a staff of 10 high-skilled employees, established a robust IP portfolio,

dealt a collaboration agreement with a major biotech company, and successfully entered it into the highly-selective European R&D consortia ND4BB ENABLE (budget €100.7 million) and GNA NOW (budget €31.4 million) dedicated to antibacterial drug development.

Since the inception of the company, Philippe has raised €5.9 million in private equity and €10.8 million  in non-dilutive funding. Prior to co-founding Nosopharm, Philippe gained experience in medicinal chemistry at Evotec (UK) and focused on natural products at CIATEJ (Mexico). Philippe holds a PhD in medicinal chemistry from the University of Montpellier.

Related Story

Appointments

 Nosopharm Welcomes New Members To Supervisory Board | Pharmtech Focus

Nosopharm Welcomes New Members To Supervisory Board

July 12 2022

Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, […]

Drug Development

 Nosopharm and GNA NOW Announce Positive Results for the Late Preclinical Development of the First-in-class Antibiotic NOSO-502 | Pharmtech Focus

Nosopharm and GNA NOW Announce Positive Results for the Late Preclinical Development of the First-in-class Antibiotic NOSO-502

June 9 2022

Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs […]